DK1653989T3 - Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel - Google Patents

Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel

Info

Publication number
DK1653989T3
DK1653989T3 DK04786310T DK04786310T DK1653989T3 DK 1653989 T3 DK1653989 T3 DK 1653989T3 DK 04786310 T DK04786310 T DK 04786310T DK 04786310 T DK04786310 T DK 04786310T DK 1653989 T3 DK1653989 T3 DK 1653989T3
Authority
DK
Denmark
Prior art keywords
peptide
amino acid
positively charged
negative bacteria
acid residues
Prior art date
Application number
DK04786310T
Other languages
Danish (da)
English (en)
Inventor
Valerie Arranz
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03292030A external-priority patent/EP1512696A1/de
Priority claimed from FR0309962A external-priority patent/FR2858772A1/fr
Application filed by Cellectis filed Critical Cellectis
Application granted granted Critical
Publication of DK1653989T3 publication Critical patent/DK1653989T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04786310T 2003-08-14 2004-08-13 Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel DK1653989T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03292030A EP1512696A1 (de) 2003-08-14 2003-08-14 Aminsäuresequenz, die den Transfer von Substanzen von Interesse in das Innere von Zellen und/oder Zellkernen erleichtern
FR0309962A FR2858772A1 (fr) 2003-08-14 2003-08-14 Composition anti bacterienne, plus particulierement contre les bacteries gram negatif, comprenant un peptide et un agent anti-bacterien avantageusement hydrophobe
PCT/FR2004/002142 WO2005018650A2 (fr) 2003-08-14 2004-08-13 Composition anti-bacterienne plus particulierement contre les bacteries gram negatif comprenent un peptide et un agent anti-bacterien avantageusement hydrophobe

Publications (1)

Publication Number Publication Date
DK1653989T3 true DK1653989T3 (da) 2009-11-23

Family

ID=34196165

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04786310T DK1653989T3 (da) 2003-08-14 2004-08-13 Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel

Country Status (12)

Country Link
US (2) US7544664B2 (de)
EP (2) EP1654285B1 (de)
JP (2) JP4633055B2 (de)
AT (1) ATE533786T1 (de)
AU (1) AU2004265159B2 (de)
BR (1) BRPI0413521A (de)
CA (2) CA2535670A1 (de)
DE (1) DE602004022056D1 (de)
DK (1) DK1653989T3 (de)
ES (2) ES2378312T3 (de)
IL (1) IL173362A0 (de)
WO (2) WO2005018650A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003595B2 (en) 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
DE602004022056D1 (de) * 2003-08-14 2009-08-27 Diatos Antibakterielle zusammensetzung, vor allem zur bekämpfung gramnegativer bakterien, umfassend ein peptid und ein vorteilhafterweise hydrophobes antibakterielles agens
EP1797901A1 (de) 2005-12-16 2007-06-20 Diatos Zelldurchlässige Peptidkonjugate zum Transfer von Nukleinsäuren in Zellen
AU2006325030B2 (en) * 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
EP1818395A1 (de) 2006-02-08 2007-08-15 Diatos Zusammensetzungen und Verfahren zur Behandlung der Lysosomen-Speichererkrankungen
EP1987055A1 (de) * 2006-02-10 2008-11-05 Dermagen AB Neue antimikrobielle peptide und deren verwendung
AU2007232206B2 (en) * 2006-03-30 2013-04-04 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
CN101516404B (zh) * 2006-03-30 2013-04-10 德莱斯医药公司 喜树碱-细胞渗透肽缀合物和含有其的药物组合物
EP1867661A1 (de) * 2006-06-12 2007-12-19 Diatos Zusammensetzungen und Verfahren zur Einschleusung von Anti-aktivierten-Ras-Antikörpern in Zellen
WO2011104382A1 (en) 2010-02-26 2011-09-01 Cellectis Use of endonucleases for inserting transgenes into safe harbor loci
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
JP6074686B2 (ja) * 2011-09-15 2017-02-08 和歌山県 ペプチド含有ポリマー、及び繊維へのペプチド固定化方法
CN102665151B (zh) * 2012-04-24 2014-12-03 烽火通信科技股份有限公司 一种分组传送网中sdh业务dcc开销的处理方法及装置
EP3019559A4 (de) 2013-08-22 2017-04-05 Sony Corporation Wasserlösliche fluoreszierende oder gefärbte farbstoffe und verfahren zu verwendung
BR112016013516A8 (pt) 2013-12-12 2020-05-19 Life Technologies Corp complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula
US11827661B2 (en) 2015-02-26 2023-11-28 Sony Group Corporation Water soluble fluorescent or colored dyes comprising conjugating groups
WO2017048092A1 (ko) * 2015-09-17 2017-03-23 서울대학교산학협력단 그람 음성균에 대한 항균 활성을 나타내는 끊어진 또는 꺾어진 나선 펩타이드 또는 펩타이드 유사체 및 이의 용도
JP2018529689A (ja) * 2015-09-17 2018-10-11 ソウル大学校産学協力団Ｓｅｏｕｌ Ｎａｔｉｏｎａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｒ＆Ｄｂ Ｆｏｕｎｄａｔｉｏｎ グラム陰性菌に対する抗菌活性を示す切断または折り畳まれたヘリックスペプチドまたはペプチド類似体およびその用途
AU2017240154B2 (en) 2016-04-01 2021-08-12 Sony Group Corporation Ultra bright dimeric or polymeric dyes
WO2017177065A2 (en) 2016-04-06 2017-10-12 Sony Corporation Ultra bright dimeric or polymeric dyes with spacing linker groups
JP7527537B2 (ja) * 2016-05-10 2024-08-05 ソニーグループ株式会社 ペプチド骨格を有する超明色ポリマー染料
EP3455299B1 (de) 2016-05-10 2024-01-17 Sony Group Corporation Zusammensetzungen mit einem polymeren farbstoff und einem cyclodextrin und verwendungen davon
EP3455300A1 (de) 2016-05-11 2019-03-20 Sony Corporation Ultrahelle dimere oder polymere farbstoffe
JP7312929B2 (ja) 2016-07-29 2023-07-24 ソニーグループ株式会社 超明色二量体またはポリマー色素およびその調製のための方法
WO2019071153A1 (en) 2017-10-05 2019-04-11 Sony Corporation PROGRAMMABLE DENDRITIC MEDICINES
KR20260011205A (ko) 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
EP3737417B1 (de) 2018-01-12 2025-08-27 Sony Group Corporation Phosphoalkyl-ribose-polymere mit biologisch aktiven verbindungen
CN111565756A (zh) 2018-01-12 2020-08-21 索尼公司 包含生物活性化合物的具有刚性间隔基团的聚合物
US12539334B2 (en) 2018-01-12 2026-02-03 Sony Group Corporation Phosphoalkyl polymers comprising biologically active agents
KR102742386B1 (ko) 2018-03-19 2024-12-16 소니그룹주식회사 형광 신호 향상을 위한 2가 금속의 사용
CN118480073A (zh) 2018-03-21 2024-08-13 索尼公司 具有连接体基团的聚合串联染料
JP7580689B2 (ja) 2018-06-27 2024-11-12 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
KR20210032434A (ko) 2018-07-13 2021-03-24 소니 주식회사 유기인산염 단위를 포함하는 백본을 갖는 중합체성 염료
WO2021062176A2 (en) 2019-09-26 2021-04-01 Sony Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (de) 2019-09-30 2022-08-10 Sony Group Corporation Nukleotidsonden
EP4256078A1 (de) 2020-12-07 2023-10-11 Sony Group Corporation Abstandslinkergruppendesign zur helligkeitsverstärkung in dimeren oder polymeren farbstoffen
WO2024261742A1 (en) 2023-06-21 2024-12-26 Nano Ghost Ltd Compositions comprising water insoluble drugs and methods of producing and using same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4526888A (en) * 1983-04-29 1985-07-02 Bristol-Myers Company Nephrotoxicity inhibitors for aminoglycoside antibiotics
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5254535A (en) * 1989-04-17 1993-10-19 The Children's Hospital Of Pennsylvania Composition and treatment with biologically active peptides and antibiotic
DK455789D0 (da) 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
WO1994028921A1 (en) * 1993-06-04 1994-12-22 Demeter Biotechnologies, Ltd. Method of treating pulmonary disease states with non-naturally occurring amphipathic peptides
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
EP0781142A4 (de) 1994-09-01 2003-04-09 Allied Medical Res Associates Zusammensetzungen und verfahren zur bereitstellung von polypeptiden
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
AU3724495A (en) 1994-09-13 1996-03-29 Prizm Pharmaceuticals, Inc. Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
US5834430A (en) 1995-05-31 1998-11-10 Biosynth S.R.L. Potentiation of antibiotics
FR2736642B1 (fr) 1995-07-10 1997-09-12 Pasteur Institut Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
US6066485A (en) 1996-03-21 2000-05-23 New York University Growth factor inducible serine/threonine phosphatase fin13
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US5967195A (en) 1997-08-01 1999-10-19 Weavexx Corporation Multi-layer forming fabric with stitching yarn pairs integrated into papermaking surface
FR2766826B1 (fr) 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
WO1999032136A1 (en) 1997-12-23 1999-07-01 Alexion Pharmaceuticals, Inc. Chimeric proteins for the treatment of diabetes
US6274712B1 (en) 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
CA2328457A1 (en) 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
EP1156816A4 (de) 1999-02-02 2004-12-29 Univ Jefferson Peptide die die aktivitäten von heparin und anderen glykosaminoglykanen oder proteoglykanen modulieren
US6855801B1 (en) 1999-02-02 2005-02-15 Thomas Jefferson University Peptides modulating activities of heparin other glycosaminoglycans or proteoglycans
JP4513145B2 (ja) * 1999-09-07 2010-07-28 ソニー株式会社 半導体装置の製造方法および研磨方法
US8003595B2 (en) * 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
FR2805821B1 (fr) * 2000-03-01 2004-01-16 Diatos Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
AU2003223923A1 (en) * 2002-05-01 2003-11-17 Pantheco A/S Peptide nucleic acid conjugates with transporter peptides
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004011033A1 (en) 2002-07-24 2004-02-05 Universite Catholique De Louvain Method for the synthesis of anthracycline-peptide conjugates
DE602004022056D1 (de) * 2003-08-14 2009-08-27 Diatos Antibakterielle zusammensetzung, vor allem zur bekämpfung gramnegativer bakterien, umfassend ein peptid und ein vorteilhafterweise hydrophobes antibakterielles agens
US20060281897A1 (en) * 2003-08-22 2006-12-14 Andre Trouet Potentialization of the activation of high molecular weight prodrugs

Also Published As

Publication number Publication date
WO2005016960A3 (en) 2005-04-07
JP2007502262A (ja) 2007-02-08
US20070042492A1 (en) 2007-02-22
EP1654285B1 (de) 2011-11-16
AU2004265159A1 (en) 2005-02-24
IL173362A0 (en) 2006-06-11
AU2004265159B2 (en) 2010-08-19
JP4633055B2 (ja) 2011-02-16
CA2535745A1 (fr) 2005-03-03
EP1653989B1 (de) 2009-07-15
US7544664B2 (en) 2009-06-09
ATE533786T1 (de) 2011-12-15
WO2005018650A3 (fr) 2005-06-16
US8293700B2 (en) 2012-10-23
EP1653989A2 (de) 2006-05-10
EP1654285A2 (de) 2006-05-10
CA2535670A1 (en) 2005-02-24
US20070259813A1 (en) 2007-11-08
ES2330115T3 (es) 2009-12-04
JP2007529194A (ja) 2007-10-25
WO2005018650A2 (fr) 2005-03-03
WO2005016960A2 (en) 2005-02-24
JP4755591B2 (ja) 2011-08-24
ES2378312T3 (es) 2012-04-11
DE602004022056D1 (de) 2009-08-27
BRPI0413521A (pt) 2006-10-10

Similar Documents

Publication Publication Date Title
DK1653989T3 (da) Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel
DE60235761D1 (de) Isoform des vegfs
PT1927597T (pt) Péptidos antibacterianos
AU2001290837A1 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
DE60037800D1 (de) Stereoselektive antifibrillogene peptide
DK1141014T3 (da) Insulinlignende vækstfaktor (IGF) i mutantvariant
BR9910158A (pt) Composições de cuidados de tecido e/ou detergente de lavanderia compreendendo uma proteina antimicrobial modificada
ATE321836T1 (de) Wässrige zusammensetzungen für oberflächebehandlung
TR200002014T2 (tr) Çok yer değiştirmeli proteaz varyantları ihtiva eden ağartıcı bileşimler.
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
ATE251448T1 (de) Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen
DE69839702D1 (de) Neue antimikrobielle polypeptide und verfahren für ihre verwendung.
AU2003231471A1 (en) Antimicrobial polypeptide and utizliation thereof
WO2001085781A3 (en) Repair of nerve damage
TR200003384T2 (tr) Arginin türevleri kullanılarak oksazolidinon antibakteriyel maddelerin etkisinin arttırılması
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»
CY1105482T1 (el) Χρηση της αζιθρομυκινης στην τοπικη αγωγη οφθαλμικων μολυνσεων
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
WO2001098327A3 (en) Glycopeptide carboxy-saccharide derivatives
MXPA05008080A (es) Inhibidores peptidicos de toxinas derivadas de la ll-37.
SE9503679D0 (sv) Antioxidants
DE60035270D1 (de) Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine
DE69615155D1 (de) Basische oxazolinamid-derivate von ge2270 und ge2270-änlichen antibiotika
DK0801655T3 (da) Basiske prolinamidderivater af GE 2270 og GE 2270-lignende antibiotika
ATE414156T1 (de) Lipase-varianten